PKTX Stock UPDATES Protokinetix Inc (PKTX) 0.0298 08/20/2014
Post# of 273330
Posted On: 08/20/2014 9:17:46 AM
Protokinetix Inc (PKTX) 0.0298 $PKTX
ProtoKinetix Welcomes Clarence E. Smith to its Board of Directors
Business Wire - Fri Jun 20, 6:00AM CDT
ProtoKinetix (OTCBB
KTX) (www.protokinetix.com) is pleased to announce the addition of entrepreneur and venture capitalist, Clarence E. Smith, to its Board of Directors. Mr. Smith brings much required, substantial financial and business experience with him as an addition to the Company's scientific accomplishments.
Umbra Applied Technologies Group Introduces Propestat
Marketwire - Fri Mar 07, 8:41AM CST
Intrepid Innovations Corporation, an (OTC:UATG )company, announced that its wholly owned subsidiary, Intrepid Medical Technologies Corporation, has introduced its blood product storage and preservation product, Propestat. The CEO of Intrepid Innovations Corporation, Chuck Winters, commented that, "Propestat, has the potential to be a paradigm shifting technology in blood product storage and platelet preservation."
ProtoKinetix Completes Sale of Exclusive Rights for AAGP(TM) Blood Preservation Applications
Business Wire - Wed Mar 05, 9:48AM CST
ProtoKinetix (OTC KTX) (www.protokinetix.com) has announced the sale of one of the numerous cell protection applications that prove to significantly increase the shelf life of delicate cells and organs by the addition of AAGP(TM). The purchaser, Intrepid Innovations Corporation, is a wholly owned subsidiary of Umbra Applied Technologies Group (OTC:UATG) and has been funded to address the world-wide demand for blood product storage, and platelet preservation.
ProtoKinetix Sells Exclusive Rights to One of the Numerous AAGP(TM) Applications
Business Wire - Mon Apr 01, 6:00AM CDT
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) has entered into the sale of exclusive rights to use it's AAGP(TM) molecule in all blood and blood platelet preservation applications. These rights have been sold to Intrepid Innovations Corporation for $2,500,000 USD after their extensive review of the AAGP(TM) molecule's ability to extend blood and blood platelet shelf life.
ProtoKinetix Welcomes Clarence E. Smith to its Board of Directors
Business Wire - Fri Jun 20, 6:00AM CDT
ProtoKinetix (OTCBB
KTX) (www.protokinetix.com) is pleased to announce the addition of entrepreneur and venture capitalist, Clarence E. Smith, to its Board of Directors. Mr. Smith brings much required, substantial financial and business experience with him as an addition to the Company's scientific accomplishments. Umbra Applied Technologies Group Introduces Propestat
Marketwire - Fri Mar 07, 8:41AM CST
Intrepid Innovations Corporation, an (OTC:UATG )company, announced that its wholly owned subsidiary, Intrepid Medical Technologies Corporation, has introduced its blood product storage and preservation product, Propestat. The CEO of Intrepid Innovations Corporation, Chuck Winters, commented that, "Propestat, has the potential to be a paradigm shifting technology in blood product storage and platelet preservation."
ProtoKinetix Completes Sale of Exclusive Rights for AAGP(TM) Blood Preservation Applications
Business Wire - Wed Mar 05, 9:48AM CST
ProtoKinetix (OTC
KTX) (www.protokinetix.com) has announced the sale of one of the numerous cell protection applications that prove to significantly increase the shelf life of delicate cells and organs by the addition of AAGP(TM). The purchaser, Intrepid Innovations Corporation, is a wholly owned subsidiary of Umbra Applied Technologies Group (OTC:UATG) and has been funded to address the world-wide demand for blood product storage, and platelet preservation. ProtoKinetix Sells Exclusive Rights to One of the Numerous AAGP(TM) Applications
Business Wire - Mon Apr 01, 6:00AM CDT
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) has entered into the sale of exclusive rights to use it's AAGP(TM) molecule in all blood and blood platelet preservation applications. These rights have been sold to Intrepid Innovations Corporation for $2,500,000 USD after their extensive review of the AAGP(TM) molecule's ability to extend blood and blood platelet shelf life.
(0)
(0)